Key facts
- Giraffe Bio raised $6.4 million in seed funding led by Orion Industrial Ventures.
- The startup develops mineral-specific chemicals to help mines recover up to 5% more copper.
- The company grows engineered microbes in a bioreactor to produce bespoke compounds.
- These compounds are inserted into a mine's existing process, replacing toxic chemicals.
- Giraffe Bio's platform can be tailored to target other minerals like gold or silver.
Giraffe Bio has secured $6.4 million in seed funding to advance its biotechnology aimed at increasing copper extraction from existing mines. The startup's approach involves producing mineral-specific biomolecules in a bioreactor, which are then introduced into a mine's current processing systems. This method aims to recover up to 5% more copper, a significant improvement over the 1% to 2% typically achieved with conventional methods.
The global demand for copper is projected to outstrip supply by 25% by 2040, driven by the expansion of AI data centers and widespread electrification. Traditional mining methods, which rely on opening costly new mines with a low success rate, are struggling to meet this demand.
Giraffe Bio's technology differentiates itself from other biotech startups like Endolith and Ceibo by producing bespoke compounds rather than directly using microbes in harsh mining environments. "We can leverage all of the biological machinery without having to deal with keeping alive a microbe, which is very complicated in [mining] environments," said Alejandro Buffo Sempé, co-founder and CEO of Giraffe Bio. The company's platform is also adaptable for extracting other minerals such as gold and silver, and for developing depressor chemicals used in the flotation process.
The seed round was led by Orion Industrial Ventures, with participation from BHP Ventures, Twynam, Air Capital, and Baruch Future Ventures. The funding will help Giraffe Bio bring its technology from the lab to commercial application.